SAN

radioref

Someone just went in there, and said GIMME SOME OF DAT SAN DICK!

cobawsky

I am relatively new buy and holder, and have been investing since January 2026. * **MSCI ACWI EUR**: 29.55% * **TSM**: 18.57% * **MSFT**: 17.79% * **TTWO**: 9.15% * **ENR.DE**: 7.97% * **Core MSCI World USD Acc**: 6.15% * **SAN.PA**: 3.85% * **CL**: 3.73% * **MSCI EM USD Acc**: 2.79% * **MSCI World Small Cap USD Acc**: 0.44% My goal is to get away from the Tech industry even more, keeping still 70% in ETFs, 20% in stable and low growth companies, and 10% for betting. What are your thoughts? What am I missing in my portfolio?

ThyJust

By the leaks, every plate on every car in GTA6 leaks of 2022-23 has "SAN ANDREAS"  plates on them, so I doubt their be a new online, Leslie Benzies former RockstarGames president stated that "GTAV and GTA ONLINE were two separate entities..." Also GTAV and GTA ONLINE came out on different days. Just saying GTA ONLINE is forever, GTA6 will come out an online as in for Leonida won't be there for about 2weeks to a month, then when online comes it comes...... 😂 Level 8000 for a reason, even Lucia necklace from GTA6 trailer 2 be in GTA ONLINE right now, even Jason's hat be GTA ONLINE right now, even my GTA ONLINE character's butt looks like Lucia's butt in that gameplay footage leak.... Rumors are Liberty City done been redone for GTA ONLINE and that's why RockstarGames took down that liberty city remake, they were hiring for people who sounded like mob boss New York accent few years ago. Another fact be is, GTA ONLINE today was the 1st of all past GTA onlines to introduce shark cards/stats/GTA$/property/vehicle-ownership/clothes an there is a saying "If you ain't first you are Last" so GTA ONLINE today will be the only GTA ONLINE that keep going, if they killed ONLINE and made people start over then no one is going to spend that much for a do over when storymode is already a do over...

_Do_The_Needful_

Hyperscalers aren't using traditional SAN/NAS devices, they are hyperconverged meaning each node has local storage, which is pooled and shared across all other nodes.

skymagic

jen-SAN kamehameha pump imminent 🙌 (DD: I just saw a clip of him eating street noodles)

Rockur

Go online to sec.edgar/search data base. This the SECURITIES AND EXCHANGE COMMISSION of the FEDERAL GOVERNMENT. “EDGAR” is their historical data base. Look up SAN JUAN MINING AND DEVELOPING COMPANY. Your family owned 1,000 Shares.

Soffatjockis

SANDISK? MORE LIKE SAN-HULK-DICK Absolutely ridiculous. -8% in AH to +8% rofl

csklmf

04/27/2026 - 05:58 AM SAN JOSE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- [POET](https://www.stocktitan.net/overview/POET/) Technologies Inc. ("[POET](https://www.stocktitan.net/overview/POET/)" or the "Company") (NASDAQ: [POET](https://www.stocktitan.net/overview/POET/)), a leader in the design and implementation of highly-integrated optical engines and light sources for artificial intelligence networks, today announced the cancellation of all purchase orders received by the Company from Celestial AI, including the ones for initial production units first disclosed (the "Purchase Orders") by the Company in a press release on April 25, 2023. Marvell Semiconductor Inc., which acquired Celestial AI, provided written notice of the cancellation to the Company on April 23, 2026. As the basis for the cancellation, Marvell indicated that the Company had made disclosures of information related to the Purchase Order and shipping information in contravention of its confidentiality obligations.

Plane-Try-6522

It isn't just the biotech sector. For the past 10, almost 20 years, most corporation have trend towards downsizing or completely eliminated their R&D department in a bid to focus on the operational and business verticals. Most corporation aren't willing to underwrite R&D risk anymore. This has led to the rise and flourishing of startups that, if successful, are acquired, to be integrated into the core business of the buying company. I had a good part of my feet on the venture capital side and quant side of my professional career. **Iova is worth looking into.** They have two lines of product: Amtagvi (FDA approved for advanced melenoma with best in - class ORR, with consistency shown years after FDA approved) and Proleukin. >**52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate** >SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced data demonstrating a best-in-class profile for commercial Amtagvi^(®) (lifileucel) with unprecedented response rates in a real-world clinical, retrospective study in patients with advanced (unresectable or metastatic) melanoma. Amtagvi is the first one-time T cell therapy for a solid tumor cancer as well as the only FDA-approved treatment for advanced melanoma patients previously treated with anti-PD-1 and targeted therapy, where applicable. >The real-world results were highlighted in an [oral presentation](https://www.iovance.com/scientific-publications-presentations/) at the 2026 Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT^(®)) and the Center for International Blood and Marrow Transplant Research (CIBMTR^(®)) in Salt Lake City, UT. >Forty-one evaluable patients with previously treated advanced melanoma received commercial Amtagvi according to the U.S. prescribing information at four authorized treatment centers. The physician-assessed confirmed objective response rate (ORR) was 44% (18/41) and the disease control rate was 73% (30/41). Response rates were higher with earlier Amtagvi treatment. The ORR was 52% (12/23) following two or fewer lines of therapy compared to an ORR of 33% (6/18) after three or more lines of therapy. The unprecedented real-world response rates also improved upon the 31% ORR in the C-144-01 clinical trial that supported the U.S. FDA accelerated approval of Amtagvi. >Lilit Karapetyan, MD, MS of H. Lee Moffitt Cancer Center & Research Institute stated, “The real-world response rate builds on existing clinical data and supports consideration of lifileucel as soon as possible after immune checkpoint inhibitor treatment. An overall response rate of 44% was observed in the full cohort, with a 52% response rate among patients treated in earlier lines of therapy. I am encouraged by the potential for an increasing number of patients to benefit as adoption of TIL therapy continues.” >Daniel Kirby, Chief Commercial Officer of Iovance, stated, “The real world Amtagvi data with impressive response rates, paired with unprecedented five-year durability and survival data, demonstrate a best-in-class profile and better outcomes in patients treated earlier.” >Previously treated advanced melanoma represents an unmet medical need with more than 8,000 annual U.S. deaths.^(1) More than half of patients treated with first line standard of care will progress within 12 months.^(2) The U.S. FDA granted accelerated approval for Amtagvi in February 2024 based on ORR and duration of response (DOR) from the C-144-01 clinical trial. The published [final five-year analysis](https://ascopubs.org/doi/10.1200/JCO-25-00765) demonstrated unprecedented durability and follow-up in previously treated advanced melanoma patients, with \~31% ORR, median DOR of 36+ months, and a 20% five-year overall survival.^(3) Iovance is conducting TILVANCE-301, a Phase 3 clinical trial in frontline advanced melanoma, to confirm clinical benefit. >1. National Cancer Institute Surveillance, Epidemiology and End Results (SEER) Program. 2025 Estimates. [https://seer.cancer.gov](https://seer.cancer.gov/) (accessed February 2026) 2. Larkin J, et al. NEJM; Robert C, et al. Lancet; Tawbi HA, et al. NEJM 3. Medina T, et al. JCO Source: [https://ir.iovance.com/news-releases/news-release-details/best-class-real-world-data-support-early-amtagvir-treatment](https://ir.iovance.com/news-releases/news-release-details/best-class-real-world-data-support-early-amtagvir-treatment) **Using what made Amtagvi/ lifileucel successful, Iova has made positive in-road into cell therapy for soft tissue sarcomas with a high 50% ORR.** >Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas *50% Objective Response Rate (ORR) in Advanced Sarcomas* >*Significant Market Opportunity with More than 8,000 Patients Diagnosed* *Annually in the U.S. and Europe* >SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced positive early data from a [pilot clinical trial](https://clinicaltrials.gov/study/NCT05607095?cond=sarcoma&intr=TIL&rank=6) led by Memorial Sloan Kettering Cancer Center (MSKCC) and supported by Iovance of lifileucel in patients with advanced (metastatic or unresectable) undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma (DDLPS) who were refractory to at least one prior line of systemic therapy. >Among the first six evaluable patients treated with lifileucel monotherapy, physician-assessed confirmed ORR by RECIST v1.1 was 50%. All evaluable patients had advanced disease, were refractory to prior therapy, and had significant disease burden, with a mean sum of diameters of 117 millimeters at baseline and a mean of more than two prior lines of therapy. Patients experienced deep responses that improved over time, consistent with lifileucel in melanoma, non-small-cell lung cancer, and other solid tumors. The safety profile was favorable and consistent with lifileucel therapy in other indications. Based on these results, Iovance plans to commence a single arm registrational trial in second-line advanced UPS and DDLPS in the second quarter of 2026 and will engage with the U.S. Food and Drug Administration (FDA) on an accelerated path to expedite approval. Iovance also plans to explore lifileucel in other high grade soft tissue sarcoma subtypes with high unmet need as part of its clinical development program. >UPS and DDLPS are high grade, aggressive soft tissue sarcomas associated with poor prognosis that impact more than 3,000 patients in the U.S. and more than 5,000 patients in Europe annually, including more than 3,500 patients with advanced disease.^(1-3) There is a high unmet medical need for new treatment options for second-line patients with recent clinical studies reporting ORRs of less than 5%, median progression-free survival (mPFS) of \~2-3 months, and median overall survival (mOS) of \~9-10 months.^(4-6) >Lauren Baker Banks, MD, PhD, Sarcoma Medical Oncologist, MSKCC, stated, “In the first clinical trial of a TIL cell therapy in UPS and DDLPS, one-time treatment with lifileucel demonstrated compelling and unprecedented response rates with the potential to address a significant unmet need in patients who are refractory to frontline standard of care. Patients with UPS and DDLPS suffer from high disease burden, poor quality of life, and a lack of effective treatments, including no approved immunotherapy options. In the second-line setting, mPFS for many patients is only a few months with mOS less than a year. We look forward to presenting these results at a medical conference in 2026.” >Dr. Brian Gastman, EVP Translational Medicine and Research at Iovance, stated, “The exciting clinical results show that lifileucel could offer a new, highly efficacious, and durable immunotherapy option in two aggressive forms of advanced sarcoma and further illustrate the promise of our TIL cell therapy platform to offer meaningful clinical benefit in multiple solid tumor cancers. Chemotherapy with extremely poor efficacy remains the second-line standard of care for these patients after progression on front-line chemotherapy. We look forward to bringing lifileucel to UPS and DDPLS patients as quickly as possible.” Source: [https://ir.iovance.com/news-releases/news-release-details/iovance-announces-positive-results-first-clinical-trial-til-cell](https://ir.iovance.com/news-releases/news-release-details/iovance-announces-positive-results-first-clinical-trial-til-cell) More: [https://ir.iovance.com/news-events/press-releases](https://ir.iovance.com/news-events/press-releases)

LouieM13

SAN FRANCISCO, Calif. (AP) — OpenAI says police arrested a man who threw a Molotov cocktail at CEO Sam Altman's home and threatened the company.

TherealCarbunc

A lot of financial stocks have gotten a big cooler with rate cuts being delayed, inflation, and macro fears - I think in some cases they are overblown even while there being real pressure on the economy. I haven't heard of San Banco is it the ticker SAN with the XRP?, I'll have to check it out more in depth to compare. From what I'm aware of SoFi's structure gives them an advantage. They hold a national bank charter and are integrating with public blockchains through SOFIUSD and Mastercard's network for 24/7 settlement. Should help global settlements for consumers or 24/7 enterprise purposes. I believe SAN has a similar advantage but their challenge lies with adapting the XRP to their legacy software?

MitchCurry

TIL Yahoo still thinks it can be relevant in the search game. >SAN FRANCISCO (AP) — Internet trailblazer Yahoo is exploring technology's next frontier with Scout, an answer engine powered by artificial intelligence. Scout seems insightful, based on its response to a question posed by The Associated Press about why one of Silicon Valley's brightest stars faded away a decade ago.

ryallen23

DCA is definitely the better move in this kind of environment. I’m adding bit by bit to INTU/SPGI/NOW/NFLX/UBER/RELX/WKL/UCG/SAN

ryallen23

last bunch of times this level of fear happened (08, 20, 22, 25) almost everyone who sold to move into cash probably regretted it hugely. im averaging down and continuing to add to all my stuff. Right now thats largely WKL, RELX, INTU, UCG, SAN, NFLX, UBER. the recovery is always faster than we expect. oil crashes from highs all of a sudden, faster than we expect. buying oil and gold during peak fear never works out.

winedogsafari

Fun fact - SAN ticker used to be STD. I guess they figured out no one wanted to willingly by an STD

msaleem

What’s your take on SAN? I saw a comment about it here recently and added it to my watchlist but haven’t had a moment to dig in yet (Pokopia). 

dansdansy

COF and SAN look promising to me

swrrrrg

LMT SAN PL I am heavy on Google as well, but to be honest, I’m going back and forth with them. I’m not as bullish as I was but I’m not quite ready to sell.

ImAshKetchum

Been riding $SAN since the high $2, don’t worry and buy more this one is a winner

Enough_Summer7073

Well SAN is one of the main financiers of spanish businesses, if the economy grows, bussinesses expand, and SAN takes a cut. And it already dominates LATAM, you can google any random street in a south american country and its very possible you'll see the Santander red sign somewhere, so If south america prospers SAN will agian take a cut from it. Regardless of agreeing or not about the financials, I think the biggest point here is that the stock market is no longer driven by logic and its literally just vibes and whatever Trump does. Trump said something, a stock dipped 13% due to it, so an irrational sell off. Just like when he pumps something irrationally it goes up and then comes down, so does the stuff he hammers irrationaly come down and then recover back to baseline. And while it is extremely hard to time whenever hes gonna pump something that suddenly prints 50% gains, I think at this point he has done the opposite so many times that we can predict its just another meaningless, irrational fear driven dip in the market. See the gazillion times he has done this with tariffs and rare earths for example

greenpride32

Spanish economy and SAN stock are not the same. SAN has little top and bottom line growth; so what would drive its valuation up? Serious question, do you even review the 10Q and 10K filings? You keep mentioning "growth" - but last earnings report is -6% YoY top line - that's referred to as "negative growth". I could selectively pick and choose dates on any stock to make it look good. The fact that you are pointing to COVID lowpoint makes your argument worse. It means everyone who bought the stock from 1996 to 2019 are underwater at the COVID lows. Do you know how much the SP500 had risen in that same time period? Being up over the long haul beats being up in a short window.

dansdansy

Thoughts on Santander (SAN) here?

Enough_Summer7073

Since covid its had a 5x, and still trending up. Adding to that Spain has one of the fastest growing economies, more than powerhouses like Germany Italy or France. Combine Spanish local growth with SAN making tons of money abroad by being among the largest banks in Mexico, Brazil, Argentina, Chile etc etc. I think theres money to be made especially when its 15% down on the week

greenpride32

I'm going to leave the politics out since this is "stocks" sub. SAN share price is flat for 25 years. Even factoring in dividends, it severely underpeforms. Some of the other companies you mention have top and bottom lines consistently trending up; whereas SAN is relatively flat. The result is the stock charts for each of them.

GoldenPresidio

They are a pure hard disk storage company Other investors can directly invest in SAN disk if interested

tysons1

What part of "NVIDIA intends to invest **up to $100 billion** in OpenAI **progressively as each gigawatt is deployed**" didn't the media understand? From the original press release: # OpenAI And NVIDIA Announce Strategic Partnership To Deploy 10 Gigawatts Of NVIDIA Systems September 22, 2025 **News** * Strategic partnership enables OpenAI to build and deploy at least 10 gigawatts of AI data centers with NVIDIA systems representing millions of GPUs for OpenAI’s next-generation AI infrastructure. * To support the partnership, NVIDIA intends to invest up to $100 billion in OpenAI progressively as each gigawatt is deployed. * The first gigawatt of NVIDIA systems will be deployed in the second half of 2026 on the NVIDIA Vera Rubin platform. SAN FRANCISCO and SANTA CLARA, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- OpenAI and NVIDIA today announced a letter of intent for a landmark strategic partnership to deploy at least 10 gigawatts of NVIDIA systems for OpenAI’s next-generation AI infrastructure to train and run its next generation of models on the path to deploying superintelligence. To support this deployment including data center and power capacity, NVIDIA intends to invest up to $100 billion in OpenAI as the new NVIDIA systems are deployed. The first phase is targeted to come online in the second half of 2026 using the NVIDIA Vera Rubin platform.... [https://investor.nvidia.com/news/press-release-details/2025/OpenAI-and-NVIDIA-Announce-Strategic-Partnership-to-Deploy-10-Gigawatts-of-NVIDIA-Systems/default.aspx](https://investor.nvidia.com/news/press-release-details/2025/OpenAI-and-NVIDIA-Announce-Strategic-Partnership-to-Deploy-10-Gigawatts-of-NVIDIA-Systems/default.aspx)

tysons1

What part of "NVIDIA intends to invest up to $100 billion in OpenAI progressively as each gigawatt is deployed" didn't the media understand? From the original press release: # OpenAI And NVIDIA Announce Strategic Partnership To Deploy 10 Gigawatts Of NVIDIA Systems September 22, 2025 **News** * Strategic partnership enables OpenAI to build and deploy at least 10 gigawatts of AI data centers with NVIDIA systems representing millions of GPUs for OpenAI’s next-generation AI infrastructure. * To support the partnership, NVIDIA intends to invest up to $100 billion in OpenAI progressively as each gigawatt is deployed. * The first gigawatt of NVIDIA systems will be deployed in the second half of 2026 on the NVIDIA Vera Rubin platform. SAN FRANCISCO and SANTA CLARA, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- OpenAI and NVIDIA today announced a letter of intent for a landmark strategic partnership to deploy at least 10 gigawatts of NVIDIA systems for OpenAI’s next-generation AI infrastructure to train and run its next generation of models on the path to deploying superintelligence. To support this deployment including data center and power capacity, NVIDIA intends to invest up to $100 billion in OpenAI as the new NVIDIA systems are deployed. The first phase is targeted to come online in the second half of 2026 using the NVIDIA Vera Rubin platform.... [https://investor.nvidia.com/news/press-release-details/2025/OpenAI-and-NVIDIA-Announce-Strategic-Partnership-to-Deploy-10-Gigawatts-of-NVIDIA-Systems/default.aspx](https://investor.nvidia.com/news/press-release-details/2025/OpenAI-and-NVIDIA-Announce-Strategic-Partnership-to-Deploy-10-Gigawatts-of-NVIDIA-Systems/default.aspx)

Dull-Tea8669

This is the dumbest shit I've read here. Congrats. There's a reason that whatever is stored on premnis stored there, and needs to be stored there in the near future, and that's only for local storage. What about NAS, SAN, DAS, how do you achieve any of these speeds in the cloud? What about storage that needs specific RAID setups? And in the end of the day where does Amazon purchase their disks from? Thin air? You are way out of your depth here

cryptohorn

SAN MARCOS - Hays County will consider a temporary ban on water-hungry developments such as data centers as San Marcos residents enter the final stages of a renewed fight against a [$1.5 billion project](https://www.statesman.com/business/technology/article/san-marcos-planning-zoning-approves-data-center-21284269.php). 

69downunder

"National defense, specifically EU," - I would go the opposite - sort of speaking - meaning got into SAN, ISP, 2 EU banks from 2 countries that seems not to rally to all guns on deck race -acc. to their nato spendings, and also 2 of which did not rally 100-150% last year like their other peers

LooseButtPlug

AXIM Biotechnologies, Inc. (OTC: AXIM) (the "Company") today announced a strategic alliance with Medical Marijuana, Inc. (OTC: MJNA) intended to research and develop applications and uses for AXIM's patent for water soluble cannabinoids. At the center of the transactions entered into between the Company and MJNA is AXIM's U.S. Patent No. 11,542,226 B2, Polyfunctional Cannabinoids (the "Patent"). AXIM assigned to MJNA a fifty percent (50%) right, title, and economic interest in the Patent and all associated intellectual property. The assignment includes rights to: Existing and future U.S. and foreign patents and applications Licensing, enforcement, and monetization proceeds Claims for past infringement and accrued royalties Concurrently, with the Patent assignment, AXIM and MJNA entered into a Consulting Agreement, whereby the Company will provide MJNA with research and development services focused on researching and developing applications and uses for the Patent technology. Skip to main content Yahoo Finance Yahoo Finance Sign in Search query Search for news or tickers This is a paid press release. Contact the press release distributor directly with any inquiries. NewMediaWire AXIM Biotechnologies, Inc. and Medical Marijuana, Inc. Enter Into Strategic Alliance to Research and Develop Applications and Uses of Patent for Water Soluble Cannabinoids NewMediaWire · AXIM Biotech NewMediaWire Thu, January 29, 2026 at 6:00 AM PST 4 min read In this article: AXIM +2.05% MJNA +50.00% Customers Don’t Mind AI—When It Works Custom Content from WSJ | Twilio • Ad SAN DIEGO, CA - January 29, 2026 (NEWMEDIAWIRE) - AXIM Biotechnologies, Inc. (OTC: AXIM) (the "Company") today announced a strategic alliance with Medical Marijuana, Inc. (OTC: MJNA) intended to research and develop applications and uses for AXIM's patent for water soluble cannabinoids. At the center of the transactions entered into between the Company and MJNA is AXIM's U.S. Patent No. 11,542,226 B2, Polyfunctional Cannabinoids (the "Patent"). AXIM assigned to MJNA a fifty percent (50%) right, title, and economic interest in the Patent and all associated intellectual property. The assignment includes rights to: Existing and future U.S. and foreign patents and applications Licensing, enforcement, and monetization proceeds Claims for past infringement and accrued royalties Concurrently, with the Patent assignment, AXIM and MJNA entered into a Consulting Agreement, whereby the Company will provide MJNA with research and development services focused on researching and developing applications and uses for the Patent technology. Catalina Valenica, AXIM President, in commenting on the transactions stated: "This alliance with MJNA presents both companies with the ability to accelerate uses of the Patent technology. The water solubility of CBD and other cannabinoids is a significant development for the improved administration and increased potency of cannabinoids. We believe that the Patent could result in the development of a drug or treatment, most likely in the form of sublingual administration, able to treat a variety of conditions including anxiety or seizures. We are very excited about this new partnership and the potential it can unlock for our respective companies." Dr. Scott, MJNA Chairman and President, stated: "We have tremendous confidence in the AXIM team's ability to provide R&D support for the development of commercialized uses of the Patent technology. The potential for developing enhanced administration of water soluble CBD and other cannabinoids for certain ailments and conditions is a major development for MJNA. In addition, MJNA already has significant knowledge and exposure to the cannabinoid market and enjoys relationships in that arena. We think that this alliance is a great fit, with tremendous opportunity for both MJNA and AXIM."

AdviceNotAskedFor

SAN

gopoohgo

MSCI Euro FN may give you enough of a spread to be ok. But your post made me look at a few biggies (BNP, SAN, DB); the value difference has evaporated

LViper914

VSEE SAN JOSE, CALIFORNIA / ACCESS Newswire / December 4, 2025 / VSee Health, Inc. (VSEE.NaE) , a leading provider of AI telehealth technology solutions, announces an upcoming webinar today with Novant Health Urgent Care, the largest urgent care provider in South Carolina.

LowWind7998

Value Plays: CMCSA | SONY | NVO | IRDM | SAN | MFG | ITUB | NU | OTC: NTDOY Nfa I just love these freakin stocks man. All about those net revenues right here. Also puts on SPYM as leverage.

dollar_llamas

Had a lot of SAN around $2.5 until last year. Would have about quadrupled my money over the last 1.5 years. Oops

LowWind7998

As long as yall know what your betting on. The problem I have is the p/e. Like you can buy SAN (ticker) for around $10 and change and it makes billions with fundamentals (one of the top earning companies worldwide) but instead... you guys are betting on perfect execution and good news as a catalyst hoping everyone ignores fundamentals. My issue is the entry price, compared to other stocks (in different categories or even the same category) , this is crazy . But I really hope it works out perfectly for you guys.

ConradMayhew

I mainly hold ETFs, so I'm not sure I can provide good advice there. A good short list is provided by the Euro Stoxx Select Dividend 30, see its composition e.g. here: https://www.blackrock.com/uk/individual/products/251787/ As you can see, that's a lot of banks plus a few utilities. I currently hold only two stocks, both in Energy (because they're still going up from when I bought): * [Engie](https://finance.yahoo.com/quote/ENGI.PA/) * [Iberdrola](https://finance.yahoo.com/quote/IBE.MC/) (Spain) I have had banks mainly this year, such as [Banco Santander](https://finance.yahoo.com/quote/SAN/) (Spain). hope this helps!

GoZukkYourself

> SAN FRANCISCO--(BUSINESS WIRE)-- SoFi Technologies, Inc. (SOFI), the one-stop shop for digital financial services, today announced the launch of SoFi Crypto, becoming the first and only nationally chartered bank where consumers can bank, borrow, invest — and now buy, sell and hold crypto – all in one place and on a platform they trust.

SlfImpr

Whoever sold their MSFT stock today, don't forget that Microsoft owns 27% of OpenAI >[https://www.reuters.com/business/openai-lays-groundwork-juggernaut-ipo-up-1-trillion-valuation-2025-10-29/](https://www.reuters.com/business/openai-lays-groundwork-juggernaut-ipo-up-1-trillion-valuation-2025-10-29/) >**Exclusive: OpenAI lays groundwork for juggernaut IPO at up to $1 trillion valuation** SAN FRANCISCO, Oct 29 - OpenAI is laying the groundwork for an initial public offering that could value the company at up to around $1 trillion, three people familiar with the matter said, in what could be one of the biggest IPOs of all time and give CEO Sam Altman access to a much larger pool of capital to pull off his ambitious agenda. OpenAI is considering filing with securities regulators as soon as the second half of 2026, some of the people said.

helpertmuner

I have some really good stocks: 1. HY9H - SK Hynix Inc. 2. DTE - Deutsche Telekom AG 3. PRCX - Prosus NV 4. SAN - Banco Santander 5. SAN1 - Sanofi 6. BBVA - Banco Bilbao Vizcaya Argenta 7. ISP - Intesa Sanpaolo 8. ENEL - Enel Spa

kaapooj

I wish I had just held GOOG on instead of buying and selling to minimize the risk. Large European banks in well-performing economies (e.g. SAN, UBS) did well too

Emperor_of_All

[https://www.reuters.com/business/world-at-work/amazon-targets-many-30000-corporate-job-cuts-sources-say-2025-10-27/](https://www.reuters.com/business/world-at-work/amazon-targets-many-30000-corporate-job-cuts-sources-say-2025-10-27/) SAN FRANCISCO, Oct 27 (Reuters) - Amazon [(AMZN.O), opens new tab](https://www.reuters.com/markets/companies/AMZN.O) is planning to cut as many as 30,000 corporate jobs beginning Tuesday, as the company works to pare expenses and compensate for overhiring during the peak demand of the pandemic, according to three people familiar with the matter. The figure represents a small percentage of Amazon’s 1.55 million total employees, but nearly 10% of the company’s roughly 350,000 corporate employees. This would represent the largest job cut at Amazon since around 27,000 jobs were eliminated starting in late 2022. An Amazon spokesperson declined to comment. Amazon has been trimming smaller numbers of jobs over the past two years across [multiple divisions](https://www.reuters.com/business/world-at-work/amazon-cuts-more-jobs-this-time-books-division-2025-06-06/), including devices, communications, podcasting and others. The cuts beginning this week may impact a variety of divisions within Amazon, including human resources, known as People Experience and Technology, devices and services and operations, among others, the people said. Managers of impacted teams were asked to undergo training on Monday for how to communicate with staff following notifications that will start going out via email tomorrow morning, the people said.

borat_he_like_you

📢 BREAKING: Sam Altman Addresses ChatGPT’s NSFW Surge — “We Might Need More GPUs.” SAN FRANCISCO, CA — December 2025 OpenAI CEO Sam Altman confirmed today that the company’s recent decision to allow verified adults to generate erotica and NSFW content has led to what he called “a historic surge in GPU utilization and human satisfaction.” *“Frankly, we underestimated how… enthusiastic people would be,” Altman said, wiping sweat from his brow during a press conference. “The erotica rollout has users generating more tokens per session than enterprise customers. We may need another $100 billion in Nvidia chips just to handle the… uh, load.”*

Bittygirl707

$POET Poet Technologies recieves "Most Innovative" Award at ECOC 2025 SAN JOSE, Calif.,Sept. 30, 2025(GLOBE NEWSWIRE) --POET Technologies Inc.("POET" or the "Company") (NASDAQ: POET), a leader in the design and implementation of highly-integrated optical engines and light sources for artificial intelligence networks, today announced it has won for the “Most Innovative Chip-scale Packaging/Optical Sub Assembly Product” at the ECOC Awards.

He-Who-Reaches

SAN DIEGO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today presented additional findings from the Phase 3 EFZO-FIT™ study of efzofitimod in 268 patients with pulmonary sarcoidosis, a major form of interstitial lung disease, in a late-breaking oral abstract presentation by Daniel Culver, D.O., Chair of the Department of Pulmonary Medicine at the Cleveland Clinic and principal investigator of the study, at the European Respiratory Society (ERS) Congress 2025 in Amsterdam, Netherlands. “Building on the positive data we presented in the topline results for the King’s Sarcoidosis Questionnaire (KSQ)-Lung score, the clinical improvements in the Fatigue Assessment Scale (FAS) and KSQ-General Health scores presented at ERS are compelling because these directly address critical symptoms and quality of life measures that profoundly impact pulmonary sarcoidosis patients,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr Pharma. “Crucially, the improvements observed for the KSQ-Lung, FAS and KSQ-General Health scores were achieved rapidly and sustained robustly throughout the study. Despite missing the primary endpoint of the study, efzofitimod has clearly demonstrated the potential to durably improve multiple disease-related health outcomes, including cough, shortness of breath, fatigue and general health. These consistent clinical benefits reinforce our belief in efzofitimod’s potential to meaningfully improve quality of life and reduce reliance on chronic steroids for pulmonary sarcoidosis patients.”

He-Who-Reaches

SAN DIEGO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced topline results from the Phase 3 EFZO-FIT™ study of efzofitimod in 268 patients with pulmonary sarcoidosis, a major form of interstitial lung disease. The study did not meet its primary endpoint of change from baseline in mean daily oral corticosteroid (OCS) dose at week 48. The change from baseline in mean daily OCS dose reduced to an average of 2.79 mg for 5.0 mg/kg efzofitimod vs 3.52 mg for placebo (p=0.3313). The study’s statistical analysis plan was designed on a hierarchical assessment basis, as such since the primary endpoint was not met, all subsequent statistical testing is reported as nominal findings.

He-Who-Reaches

SAN DIEGO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced topline results from the Phase 3 EFZO-FIT™ study of efzofitimod in 268 patients with pulmonary sarcoidosis, a major form of interstitial lung disease. The study did not meet its primary endpoint of change from baseline in mean daily oral corticosteroid (OCS) dose at week 48. The change from baseline in mean daily OCS dose reduced to an average of 2.79 mg for 5.0 mg/kg efzofitimod vs 3.52 mg for placebo (p=0.3313). The study’s statistical analysis plan was designed on a hierarchical assessment basis, as such since the primary endpoint was not met, all subsequent statistical testing is reported as nominal findings.

He-Who-Reaches

SAN DIEGO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced topline results from the Phase 3 EFZO-FIT™ study of efzofitimod in 268 patients with pulmonary sarcoidosis, a major form of interstitial lung disease. The study did not meet its primary endpoint of change from baseline in mean daily oral corticosteroid (OCS) dose at week 48. The change from baseline in mean daily OCS dose reduced to an average of 2.79 mg for 5.0 mg/kg efzofitimod vs 3.52 mg for placebo (p=0.3313). The study’s statistical analysis plan was designed on a hierarchical assessment basis, as such since the primary endpoint was not met, all subsequent statistical testing is reported as nominal findings.

He-Who-Reaches

SAN DIEGO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced topline results from the Phase 3 EFZO-FIT™ study of efzofitimod in 268 patients with pulmonary sarcoidosis, a major form of interstitial lung disease. The study did not meet its primary endpoint of change from baseline in mean daily oral corticosteroid (OCS) dose at week 48. The change from baseline in mean daily OCS dose reduced to an average of 2.79 mg for 5.0 mg/kg efzofitimod vs 3.52 mg for placebo (p=0.3313). The study’s statistical analysis plan was designed on a hierarchical assessment basis, as such since the primary endpoint was not met, all subsequent statistical testing is reported as nominal findings.

He-Who-Reaches

SAN DIEGO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced topline results from the Phase 3 EFZO-FIT™ study of efzofitimod in 268 patients with pulmonary sarcoidosis, a major form of interstitial lung disease. The study did not meet its primary endpoint of change from baseline in mean daily oral corticosteroid (OCS) dose at week 48. The change from baseline in mean daily OCS dose reduced to an average of 2.79 mg for 5.0 mg/kg efzofitimod vs 3.52 mg for placebo (p=0.3313). The study’s statistical analysis plan was designed on a hierarchical assessment basis, as such since the primary endpoint was not met, all subsequent statistical testing is reported as nominal findings.

l-kinbote

"SAN FRANCISCO--(BUSINESS WIRE)--Planet Labs PBC (NYSE:PL) today announced its intention to offer, subject to market conditions and other factors, $300,000,000 aggregate principal amount of Convertible Senior Notes due 2030 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be ..." LOL, like I said - Don't look a gift horse in the mouth!!

l-kinbote

"SAN FRANCISCO--(BUSINESS WIRE)--Planet Labs PBC (NYSE:PL) today announced its intention to offer, subject to market conditions and other factors, $300,000,000 aggregate principal amount of Convertible Senior Notes due 2030 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be ..." LOL, like I said - Don't look a gift horse in the mouth!!

SlfImpr

Yep, according to today's news from Reuters: >[https://www.reuters.com/business/autos-transportation/tesla-market-share-us-drops-lowest-since-2017-competition-heats-up-2025-09-08/](https://www.reuters.com/business/autos-transportation/tesla-market-share-us-drops-lowest-since-2017-competition-heats-up-2025-09-08/) >**Exclusive: Tesla market share in US drops to lowest since 2017 as competition heats up** >SAN FRANCISCO, Sept 8 (Reuters) - Tesla's  U.S. market share dropped to a near eight-year low in August as buyers chose electric vehicles from a growing stable of rivals over the aging lineup offered by CEO [Elon Musk](https://www.reuters.com/business/elon-musk/)'s company, according to data from research firm Cox Automotive shared exclusively with Reuters.

SlfImpr

[https://www.reuters.com/business/autos-transportation/tesla-market-share-us-drops-lowest-since-2017-competition-heats-up-2025-09-08](https://www.reuters.com/business/autos-transportation/tesla-market-share-us-drops-lowest-since-2017-competition-heats-up-2025-09-08) >**Exclusive: Tesla market share in US drops to lowest since 2017 as competition heats up** >SAN FRANCISCO, Sept 8 (Reuters) - Tesla's U.S. market share dropped to a near eight-year low in August as buyers chose electric vehicles from a growing stable of rivals over the aging lineup offered by CEO Elon Musk's company, according to data from research firm Cox Automotive shared exclusively with Reuters.

Gavage0

Key word SAN DIEGO... I'm living in fuck you nowhere and it's that price plus, along with a paycheck that's 1/3rd what you make in a big city. The longer time goes on, it's becoming, do you want a beer, OR have money to do literally anything. Soon enough, it's gonna be a choice between beer or a dinner.

Fine-Exam7697

Banco Santander SAN

ethereal3xp

Not a penny stock no longer. But SAN is killing it this year. For a bank stock its up 100 percent. SAN and BBVA. They are battling

HedgehogAccording

$SAN (Sanofi) looking hella cheap – thoughts? Trading at ~€79.50, near 52-week lows. P/E around 10, dividend yield ~5%. Solid Q2: sales up 10%, strong guidance, but market didn’t care – stock dumped 7–8% after earnings. R&D costs climbing, and US tariffs could hit. Thinking about a 5–8x long turbo but not tryna get knocked out by normal volatility. Anyone else watching this Euro pharma boi? Value gem or value trap?

nateccs

Damn that's unfortunate they timed with their earnings beat... SAN FRANCISCO--(BUSINESS WIRE)--SoFi Technologies, Inc.(NASDAQ: SOFI) (“SoFi” or the “Company”) today announced an underwritten public offering of$1.5 billionof shares of its common stock. In connection with the offering, SoFi expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering. All of the shares of common stock in the offering will be sold by SoFi.  SoFi intends to use the net proceeds from the offering for general corporate purposes, including working capital and other business opportunities.

Effective-Click2415

SAN september call 9$

Expensive-Walk3732

Another one of Cramer don’t it. It. Stocks. Wrong again buy SAN

AttentionFormer4098

Check SAN today. It is at 8.35$ now with high volume

Gloomy_MTTime420

You sure about that? \*\*I am pleased to report that following these discussions, many have indicated their intention to vote in favor of Proposal No. 2.\*\* [https://www.sec.gov/Archives/edgar/data/72444/000143774925019181/vxrt20250602\_8k.htm](https://www.sec.gov/Archives/edgar/data/72444/000143774925019181/vxrt20250602_8k.htm) **Vaxart Announces Adjournment of Annual Meeting of Stockholders**   ***Meeting adjourned to*** ***June 13, 2025*** ***at*** ***8:30 a.m. Pacific Time***   ***Vaxart*** ***encourages all stockholders of record on*** ***March 26, 2025*** ***who have not yet voted to do so by*** ***11:59 p.m. Eastern Time*** ***on*** ***June 12, 2025***   ***Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Support Proposal #2***   SOUTH SAN FRANCISCO, Calif., June 2, 2025 -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”) announced today that its 2025 annual meeting of stockholders (the “Annual Meeting”) has been adjourned to Friday, June 13, 2025 at 8:30 a.m. Pacific Time with respect to all proposals described in Vaxart’s definitive proxy statement filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 10, 2025 (the “Proxy Statement”).   “In recent days, we have engaged in constructive conversations with some of our larger stockholders to address their questions and concerns regarding the reverse stock split proposal,” said Steven Lo, Chief Executive Officer of Vaxart. “I am pleased to report that following these discussions, many have indicated their intention to vote in favor of Proposal No. 2. This shift underscores the increasing understanding of the necessity of this proposal to ensure our continued Nasdaq listing as we focus on our exciting upcoming milestones.”   The reconvened Annual Meeting will be held in a virtual-only format, which can be accessed by visiting [http://www.virtualshareholdermeeting.com/VXRT2025](http://www.virtualshareholdermeeting.com/VXRT2025) and entering the 16‐digit control number included in your Notice of Internet Availability of Proxy Materials, on your proxy card or in the instructions that accompanied your proxy materials.

ChiGuy6124

"SAN FRANCISCO/NEW YORK/BENGALURU, May 29 (Reuters) - President Donald Trump's trade war has cost companies more than $34 billion in lost sales and higher costs, according to a Reuters analysis of corporate disclosures, a toll that is expected to rise as ongoing uncertainty over tariffs paralyzes decision making at some of the world's largest companies.Across the United States, Asia and Europe, companies including Apple (AAPL.O), opens new tab, Ford (F.N), opens new tab, Porsche and Sony (6758.T), opens new tab have pulled or slashed their profit forecasts, and an overwhelming majority say the erratic nature of Trump's trade policies has made it impossible to accurately estimate costs. Reuters reviewed company statements, regulatory filings, conference and media call transcripts to pull together for the first time a snapshot of the tariff cost so far for global businesses." "While a recent pause in Sino-US trade hostilities has offered some relief and Trump has backed down from tariff threats against Europe, it is still not clear what the final trade deals will look like. A U.S. trade court on Wednesday blocked Trump's tariffs from going into effect. In this environment, strategists say companies will look to strengthen supply chains, boost near-shoring efforts, and prioritize new markets - all of which will push up costs." "Companies themselves are uncertain about the final cost. As the corporate earnings season draws to a close, Reuters found at least 42 companies have cut their forecasts and 16 have withdrawn or suspended their guidance. For instance, earlier this month, Walmart (WMT.N), opens new tab declined to provide a quarterly profit forecast and said it would raise prices, drawing a rebuke from Trump. Volvo Cars (VOLCARb.ST), opens new tab, one of the European automakers most exposed to U.S. tariffs, withdrew its earnings forecast for the next two years and United Airlines (UAL.O), opens new tab gave two different forecasts, saying it was impossible to predict the macro environment this year." ""I don't think corporations have an awful lot of visibility about anything in the future," said Rich Bernstein, CEO of Richard Bernstein Advisors in New York. Referring to withdrawn forecasts, he said, "If you take into account this uncertain world and you can't guide anybody to a number, it's safer not to guide." "Wall Street is expecting net profit for companies in the S&P 500 index to grow at an average 5.1% per quarter through April through December, versus a growth rate of 11.7% a year earlier, according to data compiled by LSEG."

ChiGuy6124

SAN FRANCISCO/NEW YORK/BENGALURU, May 29 (Reuters) - President Donald Trump's trade war has cost companies more than $34 billion in lost sales and higher costs, according to a Reuters analysis of corporate disclosures, a toll that is expected to rise as ongoing uncertainty over tariffs paralyzes decision making at some of the world's largest companies.Across the United States, Asia and Europe, companies including Apple [(AAPL.O), opens new tab](https://www.reuters.com/markets/companies/AAPL.O), Ford [(F.N), opens new tab](https://www.reuters.com/markets/companies/F.N), Porsche and Sony [(6758.T), opens new tab](https://www.reuters.com/markets/companies/6758.T) have pulled or slashed their profit forecasts, and an overwhelming majority say the erratic nature of Trump's trade policies has made it impossible to accurately estimate costs. Reuters reviewed company statements, regulatory filings, conference and media call transcripts to pull together for the first time a snapshot of the tariff cost so far for global businesses. While a recent pause in [Sino-US trade hostilities](https://www.reuters.com/world/china/us-china-reach-deal-slash-tariffs-officials-say-2025-05-12/) has offered some relief and Trump has backed down from tariff [threats against Europe](https://www.reuters.com/business/trump-extends-deadline-reach-eu-trade-deal-until-july-9-2025-05-25/), it is still not clear what the final trade deals will look like. A U.S. trade court on Wednesday [blocked Trump's tariffs](https://www.reuters.com/world/us/us-court-blocks-trumps-liberation-day-tariffs-2025-05-28/) from going into effect. In this environment, strategists say companies will look to strengthen supply chains, boost near-shoring efforts, and prioritize new markets - all of which will push up costs. "I don't think corporations have an awful lot of visibility about anything in the future," said Rich Bernstein, CEO of Richard Bernstein Advisors in New York. Referring to withdrawn forecasts, he said, "If you take into account this uncertain world and you can't guide anybody to a number, it's safer not to guide."Wall Street is expecting net profit for companies in the S&P 500 index to grow at an average 5.1% per quarter through April through December, versus a growth rate of 11.7% a year earlier, according to data compiled by LSEG.

AttentionFormer4098

Santander (SAN). They give you dividend also

AttentionFormer4098

Santander (SAN)

Own_Knowledge8501

NVIDIA’S FAVOURITE COLOR IS GREEEEEEN RAAAAHHHH🚀🚀 TAKE MY ENERGY JENSEN-SAN

Effective-Click2415

!banbet SAN 8 1w

Effective-Click2415

!banbet SAN 8 1 week

DIYPeace

Haha. I had the same rxn when I first spied it. Only stumbled upon it when reviewing $SAN shareholder materials.

BearlyNotBankrupt

SAN JOSE, Calif.--(BUSINESS WIRE)-- Super Micro Computer, Inc. (NASDAQ: SMCI) (“Supermicro” or the “Company”), a Total IT Solution Provider for AI, Cloud, Storage, and 5G/Edge, today announced that it has entered into a strategic partnership under a memorandum of understanding (“MOU”) with DataVolt to build hyperscale AI campuses initially in the Kingdom of Saudi Arabia. “Supermicro is thrilled to work together in this important effort to deliver significantly enhanced computing power for the next generation of AI infrastructure,” said Charles Liang, President and CEO of Supermicro. “We are excited to collaborate with DataVolt to bring our advanced AI systems featuring the latest direct liquid cooling technology (DLC-2) powered by local renewable, sustainable, and net-zero green technology.” This collaboration will fast-track delivery of Supermicro’s ultra-dense GPU platforms, storage, and rack PnP systems for DataVolt’s hyperscale gigawatt-class renewable and net-zero green AI campuses, giving our customers access to unprecedented scale and sustainability. Supermicro’s state-of-the-art liquid cooling solutions reduce power costs up to 40%, accelerate time-to-deployment and time-to-online, and allow data centers to run more efficiently with lower power usage effectiveness (PUE). As an end-to-end solution provider for the enterprise and cloud data centers, Supermicro will deliver a fully-tested and optimized total IT solution that includes high performance AI and compute servers, networking, storage, racks, and advanced liquid cooling technologies. Supermicro’s proven liquid cooling solutions at scale enable data center operators to rapidly deploy the latest and most performant AI infrastructure while lowering TCO by up to 20%. The collaboration is subject to negotiation and completion of one or more definitive agreements between the parties. The estimated minimum market value of the products contemplated in the transaction is $20 billion. This underscores the strategic partnership between the two companies to develop cutting-edge large scale AI infrastructure.

Key_Yesterday5264

ITUB, SAN if you like banks

looool_k_libtard

All these earnings PROVE that fourth dimensional beings are in control of our planet and we need CARMEN SAN DIEGO to come out of hiding and fight for us 🥰

BaronDavis12

$DASH In Q1 2025, we generated new quarterly records for Total Orders, Marketplace GOV, revenue, and GAAP net income. We believe these results reflect our relentless focus on building great products for consumers, merchants, and Dashers in the communities we serve around the world. We are very pleased with our financial performance and ability to execute against key strategic priorities so far in 2025. DoorDash Releases First Quarter 2025 Financial Results Rhea-AI Impact (Moderate) Rhea-AI Sentiment (Neutral) Tags earnings 05/06/2025 - 07:00 AM SAN FRANCISCO--(BUSINESS WIRE)-- DoorDash, Inc. (NASDAQ: DASH) today announced its financial results for the quarter ended March 31, 2025. In Q1 2025, we generated new quarterly records for Total Orders, Marketplace GOV, revenue, and GAAP net income. We believe these results reflect our relentless focus on building great products for consumers, merchants, and Dashers in the communities we serve around the world. We are very pleased with our financial performance and ability to execute against key strategic priorities so far in 2025. In addition to our Q1 2025 results, we are pleased to announce we have reached an agreement to acquire SevenRooms Inc., a New York City-based software company and a global leader in hospitality technology, in addition to our recently announced proposed offer to acquire Deliveroo plc. We believe both SevenRooms and Deliveroo will expand our ability to build world class services that increase our potential to grow local commerce and support our financial goals.

Mr_Cat_Pants

Everything is different, but the same... things are more moderner than before... bigger, and yet smaller... it's computers...SAN DIMAS HIGH SCHOOL FOOTBALL RULES!

dasnoob

Was on an A320 flight from SAN to DFW last week that was less than 33% full. Everyone that wanted one had an entire set of three seats to themselves.

AgentK-BB

Kikkoman makes them in the US. Remember that the US is the second biggest soybean producer, after Brazil. Chinese companies have to import soybeans before shipping the soy sauce and bean paste back to the US. Both Kikkoman and SAN-J make soy sauce in the US.

AgentK-BB

Kikkoman makes them in the US. Remember that soybeans are mostly made in the US. Chinese companies were probably buying soybeans from the US before shipping the soy sauce and bean paste back to the US. Both Kikkoman and SAN-J make soy sauce in the US.

Disastrous_Battle_14

SAVE US POWELL SAN!!!! 

chipbod

>MAGNITUDE 6 EARTHQUAKE STRIKES SAN DIEGO COUNTRY ESTATES, CALIFORNIA REGION - USGS Bull signal?

EvolvingDior

Tariffs are not going to solve problems with American manufacturing like INTC: [https://www.reuters.com/technology/intel-ceo-invested-hundreds-chinese-companies-some-with-military-ties-2025-04-10/](https://www.reuters.com/technology/intel-ceo-invested-hundreds-chinese-companies-some-with-military-ties-2025-04-10/) \> BEIJING/SAN FRANCISCO, April 10 (Reuters) - Lip-Bu Tan, the man chosen to lead Intel, the U.S.'s largest chip maker, has invested in hundreds of Chinese tech firms, including at least eight with links to the People's Liberation Army, according to a Reuters review of Chinese and U.S. corporate filings.

DIYPeace

Spanish Banks: SAN & BBVA.

stevenryl866

DRM, low float buy when unhalt ! # BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints **Thursday, 27****^(th)** **March at 8:00 am** *- XYNGARI™ achieved its primary endpoints, demonstrating highly statistically significant and clinically meaningful improvement in acne -* *- XYNGARI™ is the first once-weekly topical product candidate to demonstrate clinical benefit in a Phase 3 clinical trial for moderate-to-severe acne* \- *- Over 30 million acne patients seek treatment in the U.S. each year -* SAN DIEGO, March 26, 2025 /PRNewswire/ -- [Dermata Therapeutics, Inc.](https://c212.net/c/link/?t=0&l=en&o=4392681-1&h=1814492621&u=https%3A%2F%2Fwww.dermatarx.com%2F&a=Dermata+Therapeutics%2C+Inc.) (NASDAQ: DRMA, DRMAW)) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced positive topline results from the Company's first pivotal Phase 3 trial of XYNGARI™, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. XYNGARI^(TM) also appeared to be safe and well tolerated by patients with minimal treatment related adverse events and no serious adverse events attributed to treatment. The XYNGARI™ Phase 3 **S**pongilla **T**reatment for **A**cne **R**esearch (STAR-1) trial met all three primary endpoints by achieving a statistically significant difference when compared with placebo after 12 weeks of once weekly treatments with XYNGARI™. "I believe having a once-weekly topical product with a strong efficacy and safety profile, like XYNGARI™, would be a great addition to a dermatologist's arsenal for treating acne," commented Dr. Sunil Dhawan, MD, FAAD, FACP, clinical investigator at the Center for Dermatology Clinical Research, Inc., a participating site in the STAR-1 trial. "All FDA approved topical acne products are required to be applied at least once or twice a day, which may reduce patient compliance, so I believe having a once-weekly topical acne product like XYNGARI™ could lead to improved patient compliance," concluded Dr. Dhawan. "We are incredibly excited about these Phase 3 clinical trial results for XYNGARI™, which we believe reinforce its potential as a unique acne treatment, distinct from any existing product on the market," said Gerry Proehl, Chairman, President, and Chief Executive Officer of Dermata. "The highly statistically significant efficacy data not only confirms the results of our Phase 2b acne study but also strengthens our confidence about the upcoming XYNGARI™ Phase 3 STAR-2 trial, set to launch in the second half of 2025. With these positive Phase 3 clinical trial results, we are eager to advance discussions with potential partners interested in securing future rights to XYNGARI™," Mr. Proehl added.BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints

W4OPR

Seriously though, SAN JOSE, CA—Eric Lentell, General Counsel and Secretary of Archer Aviation Inc. (NYSE:[ACHR](https://www.investing.com/equities/archer-aviation)), recently sold 53,225 shares of the company’s Class A Common Stock. . Even their own people are not buying the dip

electionknight

SAN 9/19 $9C Big things coming

optionsplayonly

SAN JOSE, Calif.--(BUSINESS WIRE)-- Super Micro Computer, Inc.(SMCI) (“Supermicro” or the “Company”), a Total IT Solution Provider for AI, Cloud, Storage and 5G/Edge, today filed with the Securities and Exchange Commission (SEC) its Annual Report on Form 10-K for the fiscal year ended June 30, 2024 and its Quarterly Reports on Form 10-Q for the first quarter of fiscal 2025 ended September 30, 2024 and the second quarter of fiscal 2025 ended December 31, 2024.

l2osco

[https://ir.nektar.com/news-releases/news-release-details/nektar-therapeutics-receives-fast-track-designation#:\~:text=SAN%20FRANCISCO%20%2C%20Feb.%2010%2C,moderate%2Dto%2Dsevere%20atopic%20dermatitis](https://ir.nektar.com/news-releases/news-release-details/nektar-therapeutics-receives-fast-track-designation#:~:text=SAN%20FRANCISCO%20%2C%20Feb.%2010%2C,moderate%2Dto%2Dsevere%20atopic%20dermatitis) Rezpeg receives Fast Track Designation for the Treatment of Moderate-to-Severe Atopic Dermatitis - provided positive Phase II Results

AttentionFormer4098

SAN

AttentionFormer4098

SAN (SANTANDER). Catch before it leaves the penny stock world

progmakerlt

It's like 3 - 4 months now. Well, it kinda works, but it has a negative side of it... I bought Santander's (SAN) 4.3 option for March 21st for 0.48. It's price went up to 0.56, hence I sold it (+16 percent). Everything according to a plan. Sad news - there was an earnings release and bank did good. As a result, option's price skyrocketed to 1.18... On the flip side - I got my +16 percent :)

tbone99999

"SAN FRANCISCO (Reuters) - Google aims to release commercial quantum computing applications within five years" Will this revive RGTI & APLD? Calls on both for me right now.

r2002

> SAN (Santander Bank) Can you tell us a little bit about this bank? I think they are launching a new brand in the US. Are they a good bank? What makes them special?

Jambrokio

NVG (Portuguese World Leader in Office Paper + active in other sectora) SAN (Santander Bank) AMG (European Lithium)

2QuarterDollar

03-02-2025 - 22:05 SAN JOSE, Calif.—(BUSINESS WIRE)— Super Micro Computer, Inc. (SMCI), a Total IT Solution Provider for AI, Cloud, Storage, and 5G/Edge, today announced that it will provide a second quarter fiscal 2025 business update on Tuesday, February 11, 2025, at 5:00 p.m. ET / 2:00 p.m. PT.

Kooky_Lime1793

# Red Cat Announces Key Leadership Updates to Accelerate Growth Following U.S. Army Short Range Reconnaissance Program of Record Award December 02, 2024 5:30pm EST [Download as PDF](https://ir.redcatholdings.com/_assets/_e323af72173f5928f44bc4518dc39c6b/redcatholdings/news/2024-12-02_Red_Cat_Announces_Key_Leadership_Updates_to_162.pdf) SAN JUAN, Puerto Rico, Dec. 02, 2024 (GLOBE NEWSWIRE) -- [Red Cat Holdings, Inc](https://www.globenewswire.com/Tracker?data=OG0alhLubFe0hzt5VkBveWVmv04cvdv2nSWIczSQESPKbZAJbQgmteFLkH-VertxsS7DtAhAfoE6ms35F732nA==). (Nasdaq: RCAT), a drone technology company building hardware and software for military, government, and commercial operations, today announced several leadership updates to align its executive team with the company’s top priorities for scaling operations, manufacturing and meeting the needs of a fast-growing portfolio of customers. George Matus, Red Cat’s Chief Technology Officer (CTO), is departing the company and is taking the role of CTO at [Vector](https://www.globenewswire.com/Tracker?data=CzsKtag-4YEKG43VjfyjonRWewC6_MpsqFKoL_89d06R_CJMcG8Wd-JQ15RPCwdNHnj905_m-Jaf78TfeCv2ww==). As the founder of Teal Drones, George has played a vital role in Red Cat’s journey, including the recent production selection of its Black Widow drones for the U.S. Army’s SRR Program. His innovative contributions have significantly advanced Red Cat’s technology and product development. “George has been an invaluable asset to Red Cat and we fully support his transition to Chief Technology Officer at Vector,” said Jeff Thompson, Red Cat CEO. “Red Cat looks forward to partnering with Vector to equip the U.S. military and its warfighters with fully integrated, rapidly deployable technology that ensures operational success.” Chris Rill, currently Director of Partner Integration, will also transition to the role of President of Teal Drones, another Red Cat subsidiary. Chris brings nearly 20 years of experience working at the intersection of hardware and software. As a co-founder and CTO at Canary, Chris successfully delivered two award-winning connected camera security products and shipped more than 200,000 products globally. He has served as CTO for several other connected hardware companies where he's advised on product development, security, strategy, manufacturing, fundraising, and hiring. In his new role Chris will focus on scaling engineering and manufacturing and developing process efficiencies to meet the large-scale demands of the U.S. Army and Red Cat’s global customers. These leadership updates follow the recent announcement of Geoffrey Hitchcock’s promotion from General Manager of Teal Drones to Chief Revenue Officer (CRO) for Red Cat, underscoring the company’s deliberate efforts to expand its market reach and advance its leadership position in the small UAS industry. “As a fast-growing company in a rapidly evolving industry, aligning our leadership with our aggressive plans for scale is paramount,” added Thompson. “Chris and Geoff have proven track records in scaling operations, forging partnerships, and delivering innovative solutions required for the modern battlefield. With these strategic changes, we are well-positioned to meet the increasing demands of our customers while ensuring we fit into the U.S. Army’s long-term vision for medium and long-range UAS operations.”Red Cat Announces Key Leadership Updates to Accelerate Growth Following U.S. Army Short Range Reconnaissance Program of Record Award

Zealousideal-Ant2639

Appoints Douglas Beck, CPA, as Chief Financial Officer Veteran Financial Executive to Help Lead Next Phase of Company Growth SAN ANTONIO—(BUSINESS WIRE)—Nov. 22, 2024–AiAdvertising, Inc. (OTC: AIAD), an industry leader in AI-powered digital advertising solutions, today announced the appointment of Douglas Beck, CPA, a seasoned finance and accounting executive, as Chief Financial Officer, replacing John Small as part of a planned transition given the company’s uplisting strategy and inflection point. Mr. Small will remain with the company for the near term to help facilitate the transition. Douglas Beck is a senior level finance executive with over 30 years of hands-on experience and an established record with public and private companies for strategic and financial planning, business development, mergers and acquisitions, and public equity markets. Prior to joining AiAdvertising, Mr. Beck was CFO of Shiftpixy, where he assisted in raising $10 million in equity and improved the company’s financial processes and SEC reporting. Previously, as CFO with Beyond Air Inc., he helped to uplist the company to the Nasdaq and strategized to execute on the company’s short and long-term goals for equity funding, creating a critical path to raise $75 million in equity and debt. He has also served as CFO with JLM Couture, Inc., Relmada Therapeutics, Inc., iBio, Inc., and Lev Pharmaceuticals, Inc., several of which he led through the going public process. Mr. Beck holds a Bachelor of Science Degree, Accounting, from Fairleigh Dickinson University, and is a Certified Public Accountant, New York. “On behalf of our board and management team, I would like to welcome Douglas to the position, and we are privileged to have someone of his caliber and financial skill set serve as our CFO,” said AIAD CEO Jerry Hug. “I would like to thank John for his contribution in leading us to this inflection point, and welcome Douglas’ capabilities in scaling companies and leading them through the public markets journey. His achievements as well as expertise in financial management of listed companies will make a significant contribution to the operation and development of our company going forward. With his leadership, he will also steer our capital markets and uplisting strategies.”

LloydVanFunken

Look on the bright side. You used to have to wait in line when you went to Panera. After private equity bought it you can be served right away. And you don't have to spend time searching for an open table. And the food quality . . . SAN ANTONIO, Texas, March 6, 2024 (Reuters) - Fast-food chain Panera Bread has loosened its standards for animal welfare and so-called clean ingredients in its food ahead of a planned IPO, according to internal company documents seen by Reuters, shaving an estimated $21 million off its annual costs. Its stores across the U.S. were directed in late February to begin removing signs and artwork that include the phrases "No Antibiotics Ever," "Vegetarian Fed," "Grass Fed Pasture Raised," "Animal Welfare," or any mention of "Hormones," the internal documents said. The work is set to be completed by March 27, according to the documents.

Sizzlinbettas

I was a broker lived in mexico during covid I don't really agree with you but if i did want pure mexico FMX -Oxxo if you know ya know WMMVY- walmart mexico SAN-santander biting my lip...be careful